Advances in Inflammatory Bowel Diseases

Francisco Sylvester, MD, UNC School of medicine emphasized the importance of applying study findings to early interventions in treatment.

Francisco A. Sylvester, MD, UNC School of Medicine talked about the different ways in which the care of pediatric IBD differs from adult IBD.

Peter Higgins, MD, PhD, University of Michigan Health System, talked about how patients these days are often answering their own nutritional questions on the "Wild Wild West" of the Internet, so it's up to the experts to provide thorough answers to assuage their concerns.

At the 2015 Advances in Inflammatory Bowel Diseases (AIBD) meeting in Orlando, Florida, Peter Higgins, MD, PhD, the University of Michigan Health System shared his insight about the importance and value of careful nutritional guidance for IBD patients.

It’s been suggested that probiotics can help prevent relapses in ulcerative colitis, but a new analysis presented in a poster session at the 2015 Advances in Inflammatory Bowel Diseases conference (AIBD 2015) in Orlando, Florida argues that that’s not the case.

Measures in place to limit systemic steroid use for patients with inflammatory bowel disease are not as effective as they need to be. They should be replaced by a two-part model to examine drug utilization patterns that would separately consider factors associated with initiation and duration of therapy.

Hospitalization and mortality is more likely in elderly patients with inflammatory bowel disease (IBD) when compared to their younger counterparts. With 5-aminosalicylates (5-ASA) and corticosteroids becoming more popular in this age group, it’s not clear how they affect patients in the long run.

Eva Szigethy, MD, PhD, University of Pittsburgh discussed at the 2015 Advances in Inflammatory Bowel Diseases (AIBD) how to continue the conversation and implement methods to treat the burgeoning concern of opioid dependence among pediatric IBD patients.

Study results show that patients with ulcerative colitis who undergo hematopoietic stem cell transplantation (HSCT) had higher rates of opportunistic infections and inpatient mortality compared to transplant patients who did not have UC.

Miguel Regueiro, MD, University of Pittsburgh Medical Center, highlighted the hot topics in IBD at the 2015 Advances in Inflammatory Bowel Diseases.

Researchers examined the possible connection between vitamin D levels and IBD in a cohort of African American patients with IBD and a control group of those patients’ African American healthy spouses and friends.

Fatigue is two to three times more likely to appear in patients with inflammatory bowel disease (IBD) than in healthy controls. Researchers from Østfold University College in Norway found that the common symptom can lead to additional interferences.

Russell Cohen, MD, director of the Inflammatory Bowel Diseases Center at The University of Chicago Medicine continued to discuss the relevance of healthcare economics specific to IBD at the 2015 Advances in Inflammatory Bowel Diseases.

Russell Cohen, MD, director of the Inflammatory Bowel Diseases Center at The University of Chicago Medicine, discussed the progress made not only in the clinical care of IBD, but also in the basic science group and translational core at the 2015 Advances in Inflammatory Bowel Diseases meeting in Orlando, FL.

Treatment for irritable bowel syndrome (IBS) is significantly more expensive when treated in secondary care settings than it is when treated in primary care settings -- without a corresponding increase in treatment effectiveness.

The clinical features of microscopic colitis may overlap with those of ulcerative colitis and other bowel conditions.

Issues of health literacy and numeracy come into play when identifying the best strategies for explaining the risk associated with treatments for IBD.

Several predictors may help clinicians determine which patients with IBD are at risk for more severe disease and potential complications.

Although treatment for IBD is expensive, adherence reduces hospitalizations, complications, and other factors that increase the cost of care.

When IBD patients experience loss of response to therapy, the decision to escalate the dose or switch to other drugs depends on a number of factors.

What is the proper balance between mucosal healing and symptom control in treating patients with IBD?

Symptoms, not mucosal healing, should be the endpoint used in clinical practice to assess outcomes of patients with inflammatory bowel disease.

Novel biologics in development may provide alternatives to current standards of care in treating patients with refractory inflammatory bowel disease.

Adverse complications associated with IBD treatment may be uncommon, but awareness of these potential side effects is essential for proper management.

Defining, measuring, and tracking the care gastroenterologists provide to patients with IBD will improve the quality and consistency of care.

Most at-risk IBD patients have not received recommended vaccinations, even though 80% of these patients have visited their doctor in the last year.

Lessons learned in the management of children with IBD may help gastroenterologists improve the diagnosis and management of adults with the condition.

Scheduling, registration, and other information for attendees of the 2010 Advances in Inflammatory Bowel Diseases, Clinical & Research Conference.